


## ENHANCED TESTING FOR DIAGNOSIS AND PROGNOSIS

# Inflammatory bowel disease

Novel serological markers for inflammatory bowel disease (IBD) improve sensitivity and specificity to aid in differential diagnosis and provide valuable prognostic information about disease behavior.



### Inflammatory Bowel Disease (IBD) Expanded Profile (162045)



The IBD Expanded Profile was developed to be both clinically appropriate and cost-effective for patients

### Overcome diagnostic challenges

A combination of clinical findings and endoscopic, histopathologic, radiologic, and laboratory testing is used to establish the diagnosis of IBD. Diagnostic challenges arise when clinical presentation is indolent, invasive procedures are not obtainable, or results are inconclusive. In such cases, the IBD Expanded Profile may help clarify diagnosis and expedite therapeutic decisions<sup>1-12</sup> by:

- Aiding in the prompt recognition of IBD<sup>1</sup>
- Aiding in differentiating between IBD and non-IBD<sup>1</sup> forms of colitis
- Assisting in the differential diagnosis of UC versus CD in both adults and children<sup>1</sup>
- Assisting in the evaluation of patients with indeterminate colitis or IBD unclassified<sup>15,16</sup>

### Support patient prognosis and treatment decisions

The clinical course of CD is variable. Predictors of complicated disease may be used to help determine candidates for earlier and more aggressive intervention. The markers examined in Labcorp's IBD Expanded Profile have been shown to be highly specific predictors of aggressive disease behavior.<sup>1,2-8,10,13,14</sup> Our profile may help physicians:

- Gain prognostic insight by identifying CD patients at risk for progression to complicated disease<sup>1,2-8,10,13,14</sup>
- Stratify patients into disease severity/phenotypic subtypes<sup>1,2-8,10,13,14</sup>
- Evaluate candidates for colectomy or IPAA and their post-surgical prognosis<sup>16-18</sup>

## What are anti-glycan antibodies?

The serum markers specific to CD—gASCA, ACCA, ALCA, and AMCA—are antibodies directed against specific glycans (polysaccharides) found in microorganisms, such as *Candida albicans* and *Saccharomyces cerevisiae*, which are responsible for the fungal microbiota dysbiosis observed in CD.<sup>2,19</sup> These glycans modulate the immune system by acting as ligands for receptors and substrates for enzymes expressed by immune cells and intestinal epithelial cells.<sup>1,2</sup> By targeting these important yeast cell wall epitopes, anti-glycan antibodies may contribute to the altered immune response implicated in CD pathogenesis.

The diagnostic accuracy of anti-glycan antibodies has been validated by more than a dozen independent, peer-reviewed studies (n >4,000 IBD patients).

## IBD expanded diagnostic profile founded on scientific excellence

### Highly specific for CD diagnosis

- >95% specificity in distinguishing CD versus UC when two or more markers are positive<sup>2,3,6,7,10</sup>
- 88%-95% specificity to distinguish CD versus non-IBD gastrointestinal disorders<sup>14</sup>

### Enhanced sensitivity for CD with use of anti-glycan antibodies

- Combined sensitivity of 85.5% for CD<sup>9</sup>
- Addition of anti-glycan antibodies improves overall sensitivity for CD by 10%-20% from ASCA alone<sup>2,3,10</sup>
- 67% sensitivity in identifying CD patients who are ASCA negative<sup>9</sup>

### Sensitive and specific for ulcerative colitis diagnosis

- pANCA positive/gASCA negative is between 51% and 57% sensitive and 94% and 97% specific for UC<sup>11,12</sup>

### Predictive of complicated disease and progression to more severe course

- Positivity of two or more of these markers predicts faster progression to more severe disease<sup>9,13,14</sup>
- Patients with a higher number of anti-glycan antibodies and great levels have increased frequency of complicated disease behavior and need for abdominal surgery<sup>3,7,10,14</sup>

### A patient's antibody status (positive or negative) remains stable over time, irrespective of disease activity<sup>20</sup>

## Labcorp offers superior service

- Comprehensive laboratory services for the gastroenterology specialist
- Broad network of managed care health plans
- Flexible connectivity options for test ordering and reporting
- More than 2,000 patient service centers available nationwide
- Local account representation

## References

1. Bonneau J, Dumestre-Perard C, Rinaudo-Gaujoux M, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. *Autoimmun Rev*. 2015;14(3):231-245.
2. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. *Gastroenterology*. 2006;131(2):366-378.
3. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, and NOD2/CARD15 genotype in a Hungarian IBD cohort. *Am J Gastroenterol*. 2008;103(3):665-681.
4. Rieder F, Hahn P, Finsterhoelzl L, et al. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. *Inflamm Bowel Dis*. 2012;18(7):1221-1231.
5. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. *Inflamm Bowel Dis*. 2010;16(2):263-274.
6. Koutroubakis IE, Drygiannakis D, Tsirogianni A, et al. Antiglycan antibodies in Greek patients with inflammatory bowel disease. *Dig Dis Sci*. 2010;56(3):845-852.
7. Simondi D, Mengozzi G, Betteto S, et al. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. *Inflamm Bowel Dis*. 2008;14(5):645-651.
8. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. *Am J Gastroenterol*. 2009;104(6):1426-1434.
9. Malickova K, Lakatos PL, Bortlik M, Komarek V, Janatkova I, Lukas M. Anticarbhydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. *Eur J Gastroenterol Hepatol*. 2010;22(2):144-150.
10. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behavior. *Gut*. 2007;56(10):1394-13403.
11. Quinton JF, Sendid B, Reumaux D, et al. Anti-saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. *Gut*. 1998;42(6):788-791.
12. Linskens RK, Mallant-Hent RC, Groothuisink ZMA, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. *Eur J Gastroenterol Hepatol*. 2002;14(9):1013-1018.
13. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. *Inflamm Bowel Dis*. 2010;16(8):1367-1375.
14. Kaul A, et al. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. *Inflamm Bowel Dis*. 2012;18(10):1872-1884.
15. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. *Gastroenterol*. 2002;122(5):1242-1247.
16. Tremaine WJ. Diagnosis and treatment of indeterminate colitis. *Gastroenterol Hepatol*. 2011;7(12):826-828.
17. Ferrante M, Declercq S, Coopmans T, et al. Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: a role for serological markers and microbial pattern recognition receptor genes. *J Crohns Colitis*. 2008;2(2):142-151.
18. Tyler AD, Milgrom R, Xu W, et al. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. *Clin Gastroenterol Hepatol*. 2012;10(5):507-512.
19. Sokol H, Leducc V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. *Gut*. 2017;66(6):1039-1048.
20. Rieder F, Lopez R, Franke A, et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease – a longitudinal analysis. *PLoS ONE*. 2011;6(5):e18172.



Contact your local account representative for more information or visit Labcorp.com.